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In this issue of Value in Health, the ISPOR Task
Force on Use of Pharmacoeconomic/Health Eco-
nomic Information in Health Care Decision Making
presents a report with information intended to
ensure that pharmacoeconomic/health economic
(PE/HE) research is attuned to the needs of decision
makers and to provide tools they can use to inter-
pret and apply these studies [1]. After reviewing the
literature on decision makers’ attitudes toward PE/
HE evaluations, the task force has identiﬁed a
number of key decision-maker concerns that may
limit their use of results from PE/HE studies. In
addition, following a review of published guidelines
and discussions with managed care pharmacy opin-
ion leaders, the task force suggests some additional
reporting requirements to address these concerns.
Despite the authors’ recognition that a number of
issues remain to be addressed, these recommenda-
tions represent a step forward and add to the
progress that has been made toward bridging the
gap between PE/HE practitioners and decision mak-
ers. In recent years, an increasing number of man-
aged-care organizations and pharmacy beneﬁt
managers have expressed interest in obtaining PE/
HE data and many have sought training to aid their
evaluation of these studies. Some organizations are
using checklists to quickly assess the quality of PE/
HE evaluations and developing relationships with
consultants to assist in more extensive reviews.
Through use of the AMCP Format, numerous
organizations have sought PE/HE data to better
inform their P & T decision-making processes [2].
Our organization began using the AMCP Format
shortly after its inception in October 2000. We con-
ducted an orientation session for our P & T Com-
mittee in early 2001 to discuss the Format and were
encouraged to see how eager the members were to
begin receiving this information in a more consistent
manner. During the past 2.5 years, the Format has
been a helpful tool for our pharmacists who prepare
new drug monographs and has become ingrained
in our P & T process. I was therefore surprised
when our P & T Committee chairperson recently
expressed disappointment owing to our lack of
progress in this area. Despite the early promise of
dossiers for new products, he was frustrated that
very little PE/HE data from dossiers had been pre-
sented to the P & T Committee. Had we given up on
the process? If not, where were the other dossiers?
My answer provided him with a new perspective
on our processes and may shed some light on the
disconnect between producers and consumers of
PE/HE information. While there have been some
exceptions, most manufacturers do provide an
AMCP Format dossier. Unfortunately, however,
many provide only a partial submission in which
the sections on economic studies and modeling are
blank. Of those who do provide economic models,
many choose a framework that is not supported by
the clinical data. In some cases, a product has some
clinically meaningful advantages relative to existing
products, but the model addresses only acquisition
cost and rebates. These models offer little value
because we already conduct this form of analysis as
part of our routine internal process. Additionally,
these models miss the opportunity to address the
health improvements to be attained with use of the
new product. In other situations, manufacturers
have a more positive impression of their product
than we do following our review of the available
data. Here we ﬁnd cost-effectiveness analyses driven
by changes in clinical endpoints that may be sta-
tistically signiﬁcant but not necessarily clinically
meaningful. To ensure the efﬁcient use of time, we
have instructed our staff to provide only a cursory
review of cost-effectiveness analyses that are based
solely on clinical trials in which a meaningful clin-
ical advantage has not been demonstrated. As a
result, despite the receipt of numerous AMCP For-
mat dossiers, we have highlighted modeled results
from the dossiers in presentations to our P & T
Committee on only a few occasions.
While some would argue that we have unrealistic
expectations, we believe that we are taking a very
practical approach. We are not seeking incredibly
complex analyses, but rather straightforward eval-
uations of relevant questions. Yes, we want cost-
effective drugs, but they must be affordable as well.
The task force report mentions that some decision
makers may have difﬁculty understanding the
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concepts behind willingness to pay. This may be
true, but payers are well attuned to the willingness
of employer groups to pay for rapidly increasing
health-care premiums. They see the revealed prefer-
ences of clients forced to forego dental coverage for
their employees to continue to offer a pharmacy
beneﬁt. Payers who see the rolls of the uninsured
growing in the United States are beginning to take a
closer look at reference pricing and other measures
as alternatives to no coverage at all. In these circum-
stances, it should not be surprising that, for exam-
ple,  decision makers show only moderate interest in
a comparison of the cost-effectiveness of various
ARBs, while focusing much more attention on ﬁnd-
ing ways to maximize the appropriate use of ACEIs
and thiazide diuretics.
As we seek to realize the beneﬁts of PE/HE
research in an environment of double-digit spending
growth for pharmaceuticals [3], we need to con-
tinue to foster the conduct of quality research and
to invest in the resources needed to interpret it cor-
rectly. Equally importantly, however, producers and
consumers of PE/HE data alike need to be active
in applying these principles to inﬂuence decisions
within our respective environments. In many cases,
this may require changes not only in the way deci-
sions are made about speciﬁc therapies, but also in
the way the business of health care is conducted.
In the payer environment, we need to encourage
the appropriate use of safe and effective therapies
and to support the careful consideration of various
forms of evidence. Payers will need to ensure that
their staff has sufﬁcient training to evaluate PE/HE
data or arrange access to consultants who can help.
Increased dialog with those who produce PE/HE
research will be needed to improve the relevance of
modeled results. In view of the limited resources
available, payers need to encourage the use of an
affordable mix of products with proven value and
recognize that, in many cases, important health
improvements will require expansion of the drug
budget. Many PBMs need to change their business
model to begin to align their incentives with those
of their clients and improve transparency around
revenue sources, such as rebates and program fees,
which might inﬂuence product selection.
To achieve success in this area, individuals who
produce PE/HE data must also play an important
role in applying these principles. To facilitate the
cost-effective use of new and existing therapies, aca-
demics, consultants, and employees of pharmaceu-
tical companies should lobby for changes in the way
these companies study and promote their products.
A few opportunities include:
• Clinical trials should address not only the needs
of the FDA, but those of patients, providers,
and payers as well. Intermediate endpoints,
narrowly deﬁned patient populations, and
comparisons with placebo are important for
registration, but provide little basis for com-
parative value assessments. Products are seldom
cost-effective in all uses, yet payers seeking to
reimburse a product when used in its most cost-
effective manner often must instead make an all-
or-nothing decision because data about its use in
relevant subpopulations are lacking. Manufac-
turers should provide the data necessary to dem-
onstrate the value of their products at launch
rather than ask payers to assume the intrinsic
value of new products while waiting for conﬁr-
mation from a phase IV study. Findings from
ALLHAT [4] and the Women’s Health Initiative
[5], along with the ongoing debate about the rel-
ative risks and beneﬁts of COX-II inhibitors,
serve as clear reminders for payers to seek con-
ﬁrmation of value before reimbursement. In
response to insufﬁcient data at launch, many
health plans have imposed a standard delay
period before reviewing new products.
• PE/HE analyses should be integrated early in the
product development cycle to guide study design
and inﬂuence pricing decisions. Many of the cur-
rently conducted PE/HE analyses appear to be
an afterthought or addendum to clinical trials.
Because PE/HE studies are dependent on the
design and results of clinical trials, the relevance
of PE/HE research is hindered from the outset.
Although researchers may do excellent work
despite these limitations, payers often view the
endpoints chosen and the frequent assumptions
required as an indication that these analyses are
designed solely for post hoc justiﬁcation of pric-
ing decisions.
• Payers do not need bootstrap conﬁdence inter-
vals, acceptability curves, or bayesian analyses
to be convinced that generic products represent
clear cost-saving alternatives to their brand
name counterparts, and yet multiple patent list-
ings and lawsuits often needlessly delay their
market entry. “Dramatic” improvements in the
form of metabolites, enantiomers, or new deliv-
ery systems are suddenly achieved just before
patent expirations of blockbuster products.
Some pharmaceutical company Web sites tell
consumers that they may experience different
effects with a generic drug relative to the origi-
nator product despite the FDA’s clear statements
to the contrary.
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• Direct-to-consumer advertising typically does an
excellent job of educating consumers about the
existence of a product and appealing to their
sense of need, but little to encourage careful
consideration of its value relative to existing
comparators.
My background includes employment in the
pharmaceutical industry and I recognize that many
of my colleagues who perform PE/HE research to
demonstrate the value of pharmaceutical products
work diligently to prepare scientiﬁcally rigorous
analyses that will meet payer needs and encourage
the use of products with proven value. I applaud
their effort. Careful consideration of the methodo-
logical standards set forth in existing guidelines,
along with the additional reporting requirements
included in this ISPOR task force report, should
lead to improvements in the reliability and rele-
vance of PE/HE studies. However, payers do not
consider clinical and economic evidence in a vac-
uum, but rather, within the broader context of all
promotion efforts of the industry. Thus, the credi-
bility of even the best PE/HE research available may
suffer if it is produced or sponsored by a manufac-
turer whose business practices demonstrate incon-
sistent support for, and often seem to be at odds
with, the appropriate use of cost-effective and
affordable therapies.
Much progress has been made to improve the
conduct and reporting of PE/HE data. But while
payers have expressed increasing interest in PE/HE
data in recent years, many decision makers lack for-
mal training in PE/HE and little is known about
how, or if, they are actually using the information.
Some have suggested that managed care “just
doesn’t get it” and that with sufﬁcient training and
cajoling, someday they will see the true merits of
cost-effectiveness analysis and quality-of-life
research. I submit that there is an alternative expla-
nation—namely, that much of the current PE/HE
information being presented to managed care is
to some extent unnecessary, because the product
has not been shown to offer a clinically meaningful
advantage relative to existing alternatives; insufﬁ-
cient, because it does not give adequate considera-
tion to affordability; or lacking the credibility
necessary to adequately meet the information needs
of payers. I believe that until progress has been
made on these issues, further standardization of
methodologies and reporting requirements and
more training for decision makers will fail to
achieve the desired objective.
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